66630-73-7 Usage
Molecular weight
285.29 g/mol The mass of one mole of the compound, calculated from its molecular formula.
Structure
Heterocyclic compound with a benzimidazole ring The compound has a complex structure containing a benzimidazole ring, which is a heterocyclic ring system.
Functional groups
Carboxylic acid group and methyl group The compound is characterized by a carboxylic acid group (-COOH) and a methyl group (-CH3) attached to the benzimidazole ring.
Substituent
Phenyl group The compound also contains a phenyl group (-C6H5) attached to the benzimidazole ring.
Potential applications
Pharmaceutical and medicinal chemistry Due to its unique structure and potential biological activity, the compound has potential applications in the pharmaceutical and medicinal chemistry fields.
Research interest
Organic chemistry and drug development The synthesis and properties of 1-methyl-2-phenyl-1H-benzo[d]imidazole-5-carboxylic acid are of interest to researchers in the fields of organic chemistry and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 66630-73-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,6,6,3 and 0 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 66630-73:
(7*6)+(6*6)+(5*6)+(4*3)+(3*0)+(2*7)+(1*3)=137
137 % 10 = 7
So 66630-73-7 is a valid CAS Registry Number.
66630-73-7Relevant articles and documents
Benzimidazole derivatives as potent and isoform selective tumor-associated carbonic anhydrase IX/XII inhibitors
?al??kan, Burcu,Banoglu, Erden,Gür Maz, Tu??e,Nocentini, Alessio,Supuran, Claudiu T.,Uslu, Azize Gizem
, (2020/01/08)
We describe the synthesis of a series of 2-arylbenzimidazole derivatives bearing sulfonamide functionality (4a–d, 7a–c and 10) as well as hydroxamic acid (15a–b), carboxylic acid (16a–b), carboxamide (17a–b) and boronic acid (22a–b and 26) functionalities, which act as human carbonic anhydrase (hCA, EC 4.2.1.1) inhibitors. The newly synthesized benzimidazole derivatives were evaluated against 4 physiologically relevant CA isoforms (hCA I, II, IX, and XII), and especially the sulfonamide-containing benzimidazoles demonstrated intriguing inhibitory activity against tumor associated CA IX and XII with KI values in the range of 5.2–29.3 nM and 9.9–41.7 nM, respectively. Notably, compound 4c was the most potent and selective CA IX (KI = 6.6 nM) and XII (KI = 9.9 nM) inhibitor with a significant selectivity ratio over cytosolic CA I and II isoforms in the range of 3.4–25.2. In addition, compounds having hydroxamic acid (15a-b) or carboxylic acid (16a-b) functionalities resulted in greater selectivity ratios for CA IX/XII over CAI/II in the range of 4.1–121.5 although with KI values in lower micromolar potency (KIs = 0.36–0.85 μM for CA IX/XII).
